pharma · Chronic Inflammatory Demyelinating Polyneuropathy · Multifocal Motor Neuropathy · DNTH
Dianthus Therapeutics, Inc
Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc is a pharma organization headquartered in New York City, USA. It trades on NYSE under ticker DNTH. Primary therapeutic focus areas include Chronic Inflammatory Demyelinating Polyneuropathy, Mul
New York City, USA HQ
111 Employees
Public company Type
DNTH · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York City, USA
- Employees
- 111
- Programs
- 6
- Drugs
- 12
- Patents
- 2
Claseprubart
Phase 3 · small molecule · Chronic Inflammatory Demyelinating Polyneuropathy
Claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy is a Phase 3 program (small_molecule) at Dianthus Therapeutics, Inc. /DE/ with 1 ClinicalTrials.gov record(s).
Internal code DNTH103-CIDP-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dianthus Therapeutics, Inc. /DE/
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic Inflammatory Demyelinating Polyneuropathy
- Status
- active
- Trials
- 1